Side-by-side · Research reference

AOD-9604vsGDF-8

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 2HUMAN-REVIEWED10/47 cited

BAnimal-StrongHUMAN-REVIEWED23/48 cited

AOD-9604

HGH 176-191 · β3-AR Lipolytic

250–300 mcgDaily doseHeffernan 2001

Phase 2Evidence levelHeffernan 2001 Ng 2000

~30 minHalf-life

SQ · Abdomen · Daily fasted

GDF-8

TGF-β Superfamily · Negative Muscle Regulator

15–20%Muscle mass gain (MSTN−/−)

↓ AdiposityFat reduction (loss-of-function)Herman 2026 Jacquez 2026

No adversePhenotype (genetic null)Jacquez 2026

Not administered — research target for inhibition

01Mechanism of Action

Parameter

AOD-9604

GDF-8

Primary target

β3-adrenergic receptor (proposed)Ng 2000

Activin type II receptors (ActRIIA/B) on skeletal muscleIglesias 2026

Pathway

β3-AR activation → cAMP → hormone-sensitive lipase activation → triglyceride breakdown to FFA + glycerolNg 2000

MSTN → ActRII/TGFBR1 → Smad2/3 signaling → muscle protein synthesis suppression

Downstream effect

Lipolysis of adipose tissue triglycerides; FFA release for oxidation; minimal IGF-1 / insulin impactHeffernan 2001

Restricts muscle hypertrophy, limits satellite cell activation, increases proteolysis via ubiquitin-proteasome and autophagy pathwaysGong 2026 Iglesias 2026

Feedback intact?

No GH-axis or IGF-1 feedback

Yes — part of muscle-pituitary endocrine axis; muscle-derived MSTN influences FSH synthesisIglesias 2026

Origin

Synthetic modified C-terminal hexadecapeptide fragment of human GH (176-191) with N-terminal Tyr substitutionNg 2000

Endogenous myokine secreted by skeletal muscle; circulates systemically as latent complexIglesias 2026

Antibody development

—

02Dosage Protocols

Parameter

AOD-9604

GDF-8

Standard dose

250–300 mcg / dayHeffernan 2001

Anecdotal SQ range. Phase 2 trial dose 1 mg/day oral.

—

Frequency

Once daily, fasted

—

Lower / starter dose

150 mcg / day

—

Evidence basis

Phase 2 trials + animal-strongHeffernan 2001 Ng 2000

—

Duration

8–12 weeks per cycle

—

Reconstitution

Bacteriostatic water, 1 mL per 2 mg vial → 2 mg/mL

—

Timing

Morning fasted preferred (pre-cardio)

Aligns with circadian lipolysis.

—

Half-life

~30 min plasma

—

Clinical use

—

None — MSTN is a research target for inhibition, not a therapeutic peptide administered to humans

Sold by research suppliers (e.g., CertaPeptides) for in vitro / animal studies only.

Inhibition strategies

—

Monoclonal antibodies, VLP-based active immunotherapy, gene editing (CRISPR)

VLP immunogen (MS2.87-97)

—

Active immunization protocol in mice — elicits anti-MSTN antibodies without GDF11 cross-reactivityJacquez 2026

Reduces body fat, increases muscle mass and grip strength; no major safety concerns in animal models.Jacquez 2026

Dual immunization (MSTN + Activin A)

—

Combined active immunization in GH-deficient miceMansoor 2026

Improves skeletal muscle performance beyond single-target inhibition.Mansoor 2026

Gene editing outcomes

—

Precision CRISPR edits produce double-muscle phenotype, improved carcass quality in livestock

Pleiotropic effects on metabolism, reproduction, and welfare require systematic evaluation.

03Metabolic / Fat Loss Evidence

Parameter

AOD-9604

GDF-8

Primary mechanism

—

MSTN loss-of-function reduces fat accumulation independent of muscle mass effects

Human genetic evidence

—

Humans with MSTN function-disrupting variants have increased muscle mass, strength, and reduced adiposityHerman 2026

Animal model outcomes

—

VLP-immunized mice: reduced age-associated weight gain, significantly lower body fat by DEXAJacquez 2026

Adipose-muscle crosstalk

—

MSTN modulates myostatin-TAZ signaling; inhibition shifts adipose expansion toward hyperplasiaLi 2026

Metabolic benefits

—

Improved metabolic health in genetic MSTN null modelsJacquez 2026

Age-related effects

—

MSTN upregulation linked to age-dependent muscle atrophy and fat accumulation

04Side Effects & Safety

Parameter

AOD-9604

GDF-8

Injection site reaction

Mild erythema

—

GI symptoms

Rare mild nausea

—

Cardiovascular

Possible mild HR increase via β3-AR (theoretical β1 cross-reactivity)

—

IGF-1 elevation

None — designed to lack GH-axis activityHeffernan 2001

—

Insulin sensitivity

Neutral — no glucose impairmentHeffernan 2001

—

Cancer risk

No GH/IGF-1 axis activity → lower theoretical risk vs HGH

—

Pregnancy / OB

Avoid

—

Genetic null phenotype

—

No known adverse phenotypes in humans or mice with MSTN loss-of-functionJacquez 2026

Antibody cross-reactivity risk

—

Non-selective inhibitors may block GDF11, affecting cardiac and neural function

VLP immunotherapy safety

—

No major safety concerns in mice; rare hypersensitivity possibleJacquez 2026

Echocardiography

—

No cardiac abnormalities detected in MSTN-immunized miceJacquez 2026

Pleiotropic effects (gene editing)

—

MSTN editing may affect reproductive performance, metabolic homeostasis, and animal welfare

Assay variability

—

Circulating MSTN levels often fail to mirror intramuscular changes; clinical interpretation challengingIglesias 2026

Absolute Contraindications

AOD-9604

·Pregnancy / breastfeeding
·Severe cardiovascular disease (caution with β-receptor agonists)

GDF-8

·Not applicable — MSTN is not administered as a therapeutic agent

Relative Contraindications

AOD-9604

·Concurrent β-blocker therapy (theoretical antagonism)
·Pheochromocytoma

GDF-8

·Inhibition strategies contraindicated in conditions requiring maintained muscle proteostasis (theoretical)

05Administration Protocol

Parameter

AOD-9604

GDF-8

1. Reconstitution

Add 1 mL bacteriostatic water to 2 mg vial → 2 mg/mL = 200 mcg per 0.1 mL.

GDF-8 (myostatin) is not administered to humans. It is studied as a target for inhibition using monoclonal antibodies, active immunotherapy (VLP-based vaccines), or gene editing (CRISPR). Research-grade peptide supplied by vendors like CertaPeptides is intended for in vitro and animal studies only.

2. Injection site

SQ — abdomen preferred. Rotate sites.

Clinical development focuses on blocking MSTN activity via: (1) neutralizing monoclonal antibodies targeting mature MSTN or ActRII receptors; (2) active immunotherapy generating endogenous anti-MSTN antibodies (e.g., MS2.87-97 VLP platform); (3) precision gene editing to disrupt MSTN expression in livestock or therapeutic contexts.

3. Timing

Morning, fasted, ideally pre-cardio for amplified fat oxidation.

MS2.87-97 VLP administered to mice elicits anti-MSTN antibodies targeting a discrete epitope in mature MSTN protein. Immunization schedule and dose optimized for sustained antibody response without GDF11 cross-reactivity. No human protocols established.Jacquez 2026

4. Storage

Lyophilised: room temp, light-protected. Reconstituted: refrigerate, ≤30 days.

CRISPR-mediated MSTN knockout produces double-muscle phenotype in livestock (cattle, swine, sheep). Ethical frameworks and welfare assessments required; pleiotropic effects on reproduction, metabolism, and health must be systematically evaluated before human translation.

5. Needle

29–31G, 4–8 mm insulin syringe.

—

06Stack Synergy

AOD-9604

+ MOTS-c

Moderate

View MOTS-c →

AOD-9604 mobilises FFAs from adipose via β3-AR; MOTS-c upregulates AMPK / PGC-1α / FAO machinery so that mobilised FFAs are efficiently oxidised. The pathways are sequential — supply (AOD) plus demand (MOTS-c) — and produce more durable lipolytic effects than either alone in anecdotal protocols.

AOD-9604: 250–300 mcg SQ · morning fasted (daily)
MOTS-c: 5 mg SQ · 2–3× per week (pre-workout)
Primary benefit: Fat mobilisation + mitochondrial oxidation, no IGF-1 concern

GDF-8

— no documented stacks